Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04556032
Other study ID # MB-2011
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 9, 2020
Est. completion date October 30, 2020

Study information

Verified date September 2020
Source Midwest Center for Metabolic and Cardiovascular Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to assess the effects of ergothioneine at two doses, compared to placebo, on cognition, mood, and sleep in healthy adult men and women.


Description:

This will be a placebo-controlled, randomized, double-blind, parallel-arm trial. The study will consist of one screening (visit 1a, week 0), one baseline visit (visit 1b, week 0), and three treatment visits (visits 2, 3, and 4; weeks 4, 8, and 16).


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date October 30, 2020
Est. primary completion date October 30, 2020
Accepts healthy volunteers No
Gender All
Age group 55 Years to 79 Years
Eligibility Inclusion Criteria: - Individuals 55-79 years of age. - Body mass index (BMI) 18.50-34.99 kg/m2 - Non-smoker defined as no smoking for at least 6 months. - Willing to limit alcohol and caffeine consumption - Generally, in good health based on medical history and laboratory assessments - Agree to avoid consumption of mushrooms and excluded medications/supplements for the duration of the study - Willing to commit to all study procedures Exclusion Criteria: - Consumption of mushrooms more than once per week - History or presence of a psychiatric or neurologic disease including, but not limited to, epilepsy, cerebrovascular disturbance, traumatic injury, or clinically diagnosed dementia or Alzheimer's disease. - Scores =17 on the Beck Depression Inventory - History of cardiovascular complications, type 1 or type 2 diabetes mellitus, uncontrolled hypertension, or any other clinically significant disorder - History of cancer except non-melanoma skin cancer or carcinoma in situ of the cervix within the past 2 years - Use of any product containing marijuana (THC) and/or cannabidiol (CBD) including oral consumption, inhalation, & other - Any intolerance to any components of the study products - Exposure to any non-registered drug product within the past 30 days - History of drug or alcohol abuse - Considered unfit for any reason as determined by the principal investigator

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
L-Ergothioneine 10 mg/d
L-Ergothioneine 10 mg/d
L-Ergothioneine 25 mg/d
L-Ergothioneine 25 mg/d
Other:
Placebo
0 mg/d L-Ergothioneine

Locations

Country Name City State
United States Great Lakes Clinical Trials Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Midwest Center for Metabolic and Cardiovascular Research Blue California Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in the composite memory standard score from the Central Nervous System Vital Signs (CNS-VS) Test Battery Baseline to Week 16
Secondary Changes in the composite memory standard score from the Central Nervous System Vital Signs (CNS-VS) Test Battery Baseline to weeks 4 and 8
Secondary Changes in standard scores for domains relating to memory, attention, and executive function from the Central Nervous System Vital Signs (CNS-VS) Test Battery Baseline to weeks 4, 8 and 16
Secondary Changes in sleep quality based on Leeds Sleep Evaluation Questionnaire (LSEQ) Baseline to weeks 4, 8 and 16
Secondary Changes in mood based on Profile of Mood States Questionnaire (POMS) Baseline to weeks 4, 8 and 16
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1
Completed NCT04052711 - A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design Phase 1